Continue Reading Below
Shares of salesforce.com (NYSE: CRM) rose 15.5% in January of 2017, according to data from S&P Global Market Intelligence.
This month-long surge started on Jan. 4, when the company published a "state of the service" report that painted Salesforce's target market in bright, cheerful colors. The momentum continued as several analyst firms issued positive research reports on the stock, often describing it as a probable turnaround winner.
Image source: Getty Images.
Finally, as January wrapped up, rumor had it that Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) might be preparing a buyout offer for the company.
Of course, Alphabet has not presented any takeover bid for Salesforce, and I'd be surprised to see it happen. January's burst of share price gains came after a disappointing 2016 as a whole, setting the bar low for quick gains.
Is there a solid turnaround on the horizon? Salesforce does generate plenty of cash, but the stock valuation remains firmly in the nosebleed section. The stock is simply priced for absolute perfection. I'm more than comfortable staying on the sidelines -- but sudden price drops could make Salesforce shares interesting. This one goes on my long-term watch list.
10 stocks we like better than Salesforce.comWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Salesforce.com wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Anders Bylund owns shares of Alphabet (A shares). The Motley Fool owns shares of and recommends Alphabet (A and C shares). The Motley Fool recommends Salesforce.com. The Motley Fool has a disclosure policy.